Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

OurView Health Tirzepatide Review: Cost, a Self-Contradicting Membership Claim & Honest Verdict (2026)

An honest 2026 review of OurView Health tirzepatide — low starting prices via a savings club, and a site that contradicts itself on whether membership exists.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Strut Health

Injectable or sublingual tirzepatide at the same $199, for anyone who would rather not inject at all.

$149/mo injectable

FDA warning letter
FDA issued Strut Health, LLC dba Strut a warning letter in February 2026 (False & Misleading Claims/Misbranded (Telehealth)). Read the letter on FDA’s own warning-letter database.

Check Strut Health availability

OurView Health's site returned a security-challenge page on this review's verification attempt, so a flagged self-contradiction about its membership couldn't be independently reconfirmed this check. A comparison table on the site quotes "$90 without membership" against "$75 with membership," while the product cards say "No membership" and the cart charges $75 without one — a real internal inconsistency, per the ranking's own research. Every fact here comes from the company's own published program.

A self-contradicting membership claim

Worth flagging directly: OurView Health's own site is internally inconsistent about whether a paid membership exists at all. A comparison table quotes "$90 without membership" vs. "$75 with membership," but the product cards themselves say "No membership," and the cart reportedly charges $75 even without joining anything. This review's own attempt to verify directly was blocked by a security-challenge page, so treat this as a flagged inconsistency worth confirming yourself rather than a live-confirmed fact.

§ OurView Health — A Self-Contradicting Membership Claim

Source on SiteClaim
Comparison table"$90 without membership" vs. "$75 with membership"
Product cards"No membership"
CartCharges $75 without joining anything
Comparison table implies a paid membership; product cards say "No membership." This review's live check was blocked.

What OurView Health is

OurView (OurView Health) is a 100% online multi-vertical telehealth service, with an "Our View Savings Club" offering pharmacy-direct pricing on US-compounded medications, spanning TRT, HRT, BHRT, and peptides alongside GLP-1s.

What OurView Health costs

Compounded semaglutide starts from $75/month and tirzepatide from $135/month via the Savings Club — both starting-dose rates, with the cost of a titrated dose published as a ladder rather than a single price.

The brand-vs-compounded question

OurView Health dispenses compounded semaglutide and tirzepatide, not the FDA-approved branded product, and discloses this directly. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

OurView Health's real strengths: low starting prices via the Savings Club, no long-term contracts, a full legal document suite (Terms, Privacy, HIPAA Notice, Returns & Refunds), and disclosure that meds are compounded by a licensed third-party pharmacy. The trade-off is significant and worth reading closely: the site's own pages contradict each other on whether a paid membership actually exists, which makes it hard to know your real ongoing price without asking directly. This review's own verification attempt was also blocked by a security challenge, so confirm the membership terms yourself before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

OurView Health's low starting prices are appealing, but its own site contradicts itself on whether a membership is required — get that clarified in writing before you commit, since this review couldn't independently verify it live. For a provider with a genuinely unambiguous pricing structure, compare it against CoreAge Rx or Ondra Health. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

Does OurView Health require a paid membership?

Its own site contradicts itself — a comparison table implies one exists, but product cards say "No membership." This review's live verification attempt was blocked; confirm directly before committing.

How much does tirzepatide cost through OurView Health?

From $135/month for the starting dose via the Savings Club.

Does OurView Health disclose its compounding pharmacy?

It discloses meds are compounded by a licensed third-party pharmacy, but doesn't name it specifically.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Related monograph sections

View all sections